Paragon 28, Inc. Stock

Equities

FNA

US69913P1057

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 16:00:02 2024-04-26 EDT 5-day change 1st Jan Change
8.8 USD -1.90% Intraday chart for Paragon 28, Inc. -10.20% -29.20%
Sales 2024 * 255M 349M Sales 2025 * 301M 411M Capitalization 730M 997M
Net income 2024 * -36M -49.21M Net income 2025 * -26M -35.54M EV / Sales 2024 * 2.86 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 2.42 x
P/E ratio 2024 *
-20.1 x
P/E ratio 2025 *
-28.1 x
Employees 574
Yield 2024 *
-
Yield 2025 *
-
Free-Float 59.45%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.90%
1 week-10.20%
Current month-28.74%
1 month-14.15%
3 months-28.34%
6 months+7.84%
Current year-29.20%
More quotes
1 week
8.73
Extreme 8.731
10.18
1 month
8.73
Extreme 8.731
12.50
Current year
8.73
Extreme 8.731
14.79
1 year
7.95
Extreme 7.95
19.72
3 years
7.95
Extreme 7.95
25.41
5 years
7.95
Extreme 7.95
25.41
10 years
7.95
Extreme 7.95
25.41
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 09-12-31
Director of Finance/CFO 47 21-11-30
Chief Operating Officer - 22-05-31
Members of the board TitleAgeSince
Director/Board Member 73 19-12-31
Director/Board Member 72 21-11-30
Director/Board Member 67 20-06-30
More insiders
Date Price Change Volume
24-04-26 8.8 -1.90% 554,081
24-04-25 8.97 -6.95% 403,565
24-04-24 9.64 -4.08% 393,965
24-04-23 10.05 +2.66% 374,927
24-04-22 9.79 -0.10% 280,226

Delayed Quote Nyse, April 26, 2024 at 04:00 pm

More quotes
Paragon 28, Inc. is a medical device company. The Company develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products and product families include plates and plating systems, screws, staples, and nails to address all foot and ankle procedures, including fracture fixation, forefoot, or hallux valgus, which includes bunion and hammertoe, ankle, flatfoot, or progressive collapsing foot deformity (PCDF), Charcot foot and Ortho biologics. It provides a comprehensive portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. The Company’s suite of surgical solutions comprises 75 product systems, including approximately 9,200 SKUs, which comprises of approximately 6,800 implants, 1,400 instruments and 1,000 disposable and other SKUs. Its products are available in a variety of sizes and configurations to suit the individual patient’s anatomical and surgical requirements.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
8.8 USD
Average target price
18 USD
Spread / Average Target
+104.55%
Consensus